Peptide quality control (QC) encompasses a systematic testing regimen to ensure identity, purity, potency, safety, and stability of the final product. This guide details the complete QC panel for research, preclinical, and clinical-grade peptides.

1. QC Framework Overview

Testing by Application Grade

Test	Research	Preclinical	Clinical	Commercial
Identity (MS)	✓	✓	✓	✓
Purity (HPLC)	>95%	>98%	>98.5%	>99%
Amino acid analysis	Optional	✓	✓	✓
Sequence confirmation	Optional	✓	✓	✓
Residual solvents	—	✓	✓	✓
Water content	—	✓	✓	✓
Endotoxin	—	✓	✓	✓
Microbial limits	—	✓	✓	✓
Heavy metals	—	—	✓	✓
Stability (ICH)	—	—	✓	✓
Potency	—	✓	✓	✓

2. Identity Testing

Mass Spectrometry

Method: ESI-MS or MALDI-TOF

Acceptance:

• Measured mass within ±2 Da of theoretical mass (monoisotopic)
• For peptides >3 kDa, ±5 Da acceptable

Calculation: Theoretical monoisotopic mass = Σ(amino acid masses) – (n-1) × 18.015 + terminal groups

Amino Acid Analysis (AAA)

Method: Acid hydrolysis → derivatization → HPLC/CE

Procedure:

1. Dissolve 0.1–1 mg peptide in 6 M HCl
2. Hydrolyze at 110°C for 24 hr (standard) or 16 hr (partial)
3. Derivatize with OPA/FMOC or AQC
4. Separate by RP-HPLC
5. Quantify each amino acid vs. norleucine internal standard

Acceptance:

• Each amino acid within ±10% of theoretical (±15% for Trp, Cys, Met)
• No unexpected amino acids

Sequence Confirmation

Methods:

• Edman degradation (N-terminal, up to 50 residues)
• LC-MS/MS (full sequence coverage)

Acceptance:

• Complete sequence match
• No deletion or insertion sequences

3. Purity Testing

RP-HPLC

Method:

• Column: C18, 2.1 × 150 mm, 1.7 µm
• Mobile phase: 0.1% TFA/H₂O (A), 0.1% TFA/MeCN (B)
• Gradient: 5–65% B over 20 min
• Detection: UV 220 nm (amide bond), 280 nm (aromatic)

Acceptance:

• Research grade: ≥95% (area normalization)
• Preclinical: ≥98%
• Clinical: ≥98.5%
• Commercial: ≥99%

Impurity Identification

Procedure:

1. Collect HPLC fractions containing impurities >0.5%
2. Analyze by LC-MS/MS
3. Assign impurity identity (deletion, truncated, oxidized, etc.)

Reporting: List all impurities >0.5% and any impurities >0.2% for clinical-grade material.

ICH Q3A/Q3B Compliance

Per ICH guidelines:

• Report threshold for identification: 0.10% (clinical)
• Report threshold for qualification: 0.15% (clinical)
• Threshold for acceptance: 0.15% (clinical)

4. Residual Solvent Testing

Method: GC-HS (Headspace Gas Chromatography)

Solvent	ICH Class	Limit (ppm)	Method
DMF	2	880	USP <467>
NMP	2	530	USP <467>
DCM	2	600	USP <467>
TFA	3	—	ICP-MS (fluoride)
MeOH	2	3000	USP <467>
Et₂O	3	5000	USP <467>
Acetonitrile	2	410	USP <467>
Piperidine	2	—	LC-MS

TFA Quantification

TFA (trifluoroacetic acid) is a common cleavage agent that is difficult to remove:

1. Dissolve peptide in 50% MeOH/H₂O
2. Analyze by ion chromatography or ¹⁹F NMR
3. Acceptance: <0.1% w/w for clinical grade

5. Water Content

Method: Karl Fischer Titration

Procedure:

1. Dissolve 10–50 mg peptide in anhydrous methanol
2. Titrate with Karl Fischer reagent
3. Report as % w/w water

Acceptance:

• Lyophilized peptides: <5% w/w
• Amorphous powders: <3% w/w
• Oils/solutions: per specification

6. Endotoxin Testing

Method: LAL (Limulus Amebocyte Lysate) Assay

Sensitivity: 0.005–0.5 EU/mL

Acceptance:

• Research grade: <10 EU/mg
• Preclinical: <1 EU/mg
• Clinical: <0.25 EU/mg (FDA requirement for parenteral)

Mitigation: Endotoxin removal by:

• Filtration through 0.22 µm with endotoxin-retentive membrane
• Anion-exchange chromatography
• Triton X-114 phase separation

7. Microbial Testing

Tests Required

Test	Method	Acceptance
Bioburden	USP <61>	<100 CFU/g
Sterility	USP <71>	Sterile (for injectable)
Bacterial endotoxins	USP <85>	<0.25 EU/mL
Particulate matter	USP <788>	Meets limits

Sterility Assurance

For injectable peptides:

• Terminal sterilization (gamma irradiation, 25 kGy) if possible
• Aseptic processing if terminal sterilization not feasible
• Sterility testing per USP <71>

8. Heavy Metal Testing

ICP-MS Analysis

Metal	Limit (ppm)	Source
As	<1.5	Reagent contamination
Cd	<0.25	Reagent contamination
Hg	<0.5	Reagent contamination
Pb	<0.5	Reagent contamination
Co	<0.5	Catalyst residue
Ni	<0.5	Metal vessel corrosion
Cr	<0.5	Metal vessel corrosion

9. Potency Testing

Bioassay

• Cell-based assay measuring biological activity
• Express as % relative potency vs. reference standard
• Acceptance: 80–120% relative potency

Binding Assay

• SPR (surface plasmon resonance) for receptor binding
• ELISA for ligand-receptor interactions
• Report K_d and EC₅₀ values

Specific Activity

• U/mg or U/µmol
• Compare to literature or in-house reference

10. Stability Testing

ICH Q1A Guidelines

Condition	Temperature	Humidity	Duration
Long-term	25°C ± 2°C	60% ± 5% RH	12–24 months
Accelerated	40°C ± 2°C	75% ± 5% RH	6 months
Stress	50°C ± 2°C	Ambient	2 weeks
Freeze-thaw	-20°C ↔ 25°C	—	3 cycles
Photostability	ICH Q1B	—	As required

Stability Parameters

Parameter	Method	Acceptance
Purity	HPLC	Within 2% of initial
Identity	MS	Mass unchanged
Appearance	Visual	No color change
Water content	Karl Fischer	Within 1% of initial
Potency	Bioassay	>80% of initial

References

1. ICH Q1A(R2). Stability Testing of New Drug Substances and Products.
2. ICH Q3A(R2). Impurities in New Drug Substances.
3. ICH Q3B(R2). Impurities in New Drug Products.
4. USP General Chapters <61>, <71>, <85>, <467>.
5. European Pharmacopoeia 2.2.29 (Liquid Chromatography).

Further Reading

• Peptide Stability Testing — Detailed stability protocols
• GMP Manufacturing — Production under GMP
• Analytical Methods — All analytical techniques